{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:03:34Z","timestamp":1793808214275,"version":"4.6.1"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurosci."],"abstract":"<jats:p>GM1 gangliosidosis (GM1) is a rare but fatal neurodegenerative disease caused by dysfunction or lack of production of lysosomal enzyme, \u03b2-galactosidase, leading to accumulation of substrates. The most promising treatments for GM1, include enzyme replacement therapy (ERT), substrate reduction therapy (SRT), stem cell therapy and gene editing. However, effectiveness is limited for neuropathic GM1 due to the restrictive nature of the blood\u2013brain barrier (BBB). ERT and SRT alleviate substrate accumulation through exogenous supplementation over the patient\u2019s lifetime, while gene editing could be curative, fixing the causative gene, <jats:italic>GLB1<\/jats:italic>, to enable endogenous enzyme activity. Stem cell therapy can be a combination of both, with <jats:italic>ex vivo<\/jats:italic> gene editing of cells to cause the production of enzymes. These approaches require special considerations for brain delivery, which has led to novel formulations. A few therapeutic interventions have progressed to early-phase clinical trials, presenting a bright outlook for improved clinical management for GM1.<\/jats:p>","DOI":"10.3389\/fnins.2024.1392683","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T04:34:26Z","timestamp":1714106066000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Therapeutic developments for neurodegenerative GM1 gangliosidosis"],"prefix":"10.3389","volume":"18","author":[{"given":"Dorian","family":"Foster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucian","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.nbd.2004.04.012","article-title":"Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease","volume":"16","author":"Andersson","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1007\/s11940-013-0256-3","article-title":"Enzyme replacement in neuronal storage disorders in the pediatric population","volume":"15","author":"Augustine","year":"2013","journal-title":"Curr. Treat. Options Neurol."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e13468","DOI":"10.1371\/journal.pone.0013468","article-title":"AAV-mediated gene delivery in adult GM1-gangliosidosis mice corrects lysosomal storage in CNS and improves survival","volume":"5","author":"Baek","year":"2010","journal-title":"PLoS One"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1038\/mt.2013.86","article-title":"Therapeutic response in feline Sandhoff disease despite immunity to intracranial gene therapy","volume":"21","author":"Bradbury","year":"2013","journal-title":"Mol. Ther."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/sj.mt.6300004","article-title":"Complete correction of enzymatic deficiency and neurochemistry in the GM1-gangliosidosis mouse brain by neonatal adeno-associated virus-mediated gene delivery","volume":"15","author":"Broekman","year":"2007","journal-title":"Mol. Ther."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ymgme.2008.04.012","article-title":"GM1 gangliosidosis: review of clinical, molecular, and therapeutic aspects","volume":"94","author":"Brunetti-Pierri","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"13532","DOI":"10.1074\/jbc.RA119.009811","article-title":"Intracerebroventricular enzyme replacement therapy with \u03b2-galactosidase reverses brain pathologies due to GM1 gangliosidosis in mice","volume":"295","author":"Chen","year":"2020","journal-title":"J. Biol. Chem."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.5734\/JGM.2021.18.1.16","article-title":"GLB1 -related disorders: GM1 gangliosidosis and Morquio B disease","volume":"18","author":"Cho","year":"2021","journal-title":"J. Genet. Med."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13052-018-0562-1","article-title":"Enzyme replacement therapy: efficacy and limitations","volume":"44","author":"Concolino","year":"2018","journal-title":"Ital. J. Pediatr."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ymgme.2015.12.002","article-title":"Enzyme replacement for GM1-gangliosidosis: uptake, lysosomal activation, and cellular disease correction using a novel \u03b2-galactosidase: RTB lectin fusion","volume":"117","author":"Condori","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"114464","DOI":"10.1016\/j.addr.2022.114464","article-title":"Current treatment options and novel nanotechnology-driven enzyme replacement strategies for lysosomal storage disorders","volume":"188","author":"Del Grosso","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s11011-017-0044-y","article-title":"The treatment of juvenile\/adult GM1-gangliosidosis with Miglustat may reverse disease progression","volume":"32","author":"Deodato","year":"2017","journal-title":"Metab. Brain Dis."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ymgme.2008.02.005","article-title":"Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis","volume":"94","author":"Elliot-Smith","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e1371","DOI":"10.1002\/mgg3.1371","article-title":"Substrate reduction therapy with Miglustat in pediatric patients with GM1 type 2 gangliosidosis delays neurological involvement: a multicenter experience","volume":"8","author":"Fischetto","year":"2020","journal-title":"Mol. Genet. Genomic Med."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2217\/nnm-2023-0300","article-title":"Optimizing enzyme-responsive polymersomes for protein-based therapies","volume":"19","author":"Foster","year":"2024","journal-title":"Nanomedicine"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/mt.2011.72","article-title":"Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates","volume":"19","author":"Gray","year":"2011","journal-title":"Mol. Ther."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.omtm.2017.07.005","article-title":"Lipidomic evaluation of feline neurologic disease after AAV gene therapy","volume":"6","author":"Gray-Edwards","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.omtm.2019.11.023","article-title":"7T MRI predicts amelioration of neurodegeneration in the brain after AAV gene therapy","volume":"17","author":"Gray-Edwards","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.ymthe.2017.01.009","article-title":"Novel biomarkers of human GM1 Gangliosidosis reflect the clinical efficacy of gene therapy in a feline model","volume":"25","author":"Gray-Edwards","year":"2017","journal-title":"Mol. Ther."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/brain\/awab309","article-title":"Intravenous delivery of adeno-associated viral gene therapy in feline GM1 gangliosidosis","volume":"145","author":"Gross","year":"2022","journal-title":"Brain"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119558","article-title":"Ganglioside GM1 and the central nervous system","volume":"24","author":"Guo","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"9002","DOI":"10.1021\/acsomega.7b01230","article-title":"Intracellular delivery of \u03b2-galactosidase enzyme using arginase-responsive dextran sulfate\/poly- l -arginine capsule for lysosomal storage disorder","volume":"2","author":"Gupta","year":"2017","journal-title":"ACS Omega"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nri977","article-title":"A road less travelled: large animal models in immunological research","volume":"3","author":"Hein","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe toxicity in nonhuman Primates and piglets following high-dose intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1089\/hum.2018.206","article-title":"A single injection of an optimized adeno-associated viral vector into cerebrospinal fluid corrects neurological disease in a murine model of gm1 gangliosidosis","volume":"31","author":"Hinderer","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/S0140-6736(95)92597-X","article-title":"Allogeneic bone marrow transplantation for lysosomal storage diseases","volume":"345","author":"Hoogerbrugge","year":"1995","journal-title":"Lancet"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1002\/cbf.3887","article-title":"Gene therapy approaches for GM1 gangliosidosis: focus on animal and cellular studies","volume":"41","author":"Hosseini","year":"2023","journal-title":"Cell Biochem. Funct."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1002\/ana.26756","article-title":"Life-limiting peripheral organ dysfunction in feline Sandhoff disease emerges after effective CNS gene therapy","volume":"94","author":"Johnson","year":"2023","journal-title":"Ann. Neurol."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1194\/jlr.M400411-JLR200","article-title":"Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice","volume":"46","author":"Kasperzyk","year":"2005","journal-title":"J. Lipid Res."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1046\/j.1471-4159.2004.02381.x","article-title":"N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis","volume":"89","author":"Kasperzyk","year":"2004","journal-title":"J. Neurochem."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.pneurobio.2016.10.002","article-title":"Emerging therapies for neuropathic lysosomal storage disorders","volume":"152","author":"Kelly","year":"2017","journal-title":"Prog. Neurobiol."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.2217\/nnm-2017-0221","article-title":"Polyethylene glycol-b-poly (lactic acid) polymersomes as vehicles for enzyme replacement therapy","volume":"12","author":"Kelly","year":"2017","journal-title":"Nanomedicine"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.omtm.2023.05.010","article-title":"Enzyme replacement with transferrin receptor-targeted \u03b1-L-iduronidase rescues brain pathology in mucopolysaccharidosis I mice","volume":"29","author":"Kida","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref35","first-page":"3","article-title":"The Larsen lab: a Center for Nanotherapeutic Strategies in the central nervous system (CNS 2)","volume-title":"J. South Carolina Acad. Sci.","author":"Larsen","year":"2023"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1172\/JCI5542","article-title":"A genetic model of substrate deprivation therapy for a glycosphingolipid storage disorder","volume":"103","author":"Liu","year":"1999","journal-title":"J. Clin. Invest."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"S372","DOI":"10.1016\/j.ymthe.2005.07.507","article-title":"Adenoviral-mediated expression of brain-derived Neuroptrophic factor or Neurotrophin-3 promotes sprouting of lesioned serotonergic axons in the central nervous system","volume":"11","author":"Martin","year":"2005","journal-title":"Mol. Ther."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"231ra48","DOI":"10.1126\/scitranslmed.3007733","article-title":"Sustained normalization of neurological disease after intracranial gene therapy in a feline model","volume":"6","author":"McCurdy","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/jhg.2009.70","article-title":"Structural bases of GM1 gangliosidosis and Morquio B disease","volume":"54","author":"Morita","year":"2009","journal-title":"J. Hum. Genet."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1002\/bab.2137","article-title":"\u03b2-Galactosidase: from its source and applications to its recombinant form","volume":"69","author":"Movahedpour","year":"2022","journal-title":"Biotechnol. Appl. Biochem."},{"key":"ref9","article-title":"Clinicaltrials.gov. Available at:","year":"2024"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"734878","DOI":"10.3389\/fgene.2021.734878","article-title":"GM1 Gangliosidosis\u2014A Mini-Review","volume":"12","author":"Nicoli","year":"2021","journal-title":"Front. Genet."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"997607","DOI":"10.3389\/fceng.2022.997607","article-title":"Enzyme-responsive polymersomes ameliorate autophagic failure in a cellular model of GM1 gangliosidosis","volume":"4","author":"Paruchuri","year":"2022","journal-title":"Front. Chem. Eng."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrd.2017.214","article-title":"Emptying the stores: lysosomal diseases and therapeutic strategies","volume":"17","author":"Platt","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1098\/rstb.2003.1279","article-title":"Substrate reduction therapy in mouse models of the glycosphingolipidoses","volume":"358","author":"Platt","year":"2003","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"8362","DOI":"10.1016\/S0021-9258(17)37202-2","article-title":"N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis","volume":"269","author":"Platt","year":"","journal-title":"J. Biol. Chem."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"27108","DOI":"10.1016\/S0021-9258(18)47132-3","article-title":"N-butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing","volume":"269","author":"Platt","year":"","journal-title":"J. Biol. Chem."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"100748","DOI":"10.1016\/j.ymgmr.2021.100748","article-title":"Examination of a blood-brain barrier targeting \u03b2-galactosidase-monoclonal antibody fusion protein in a murine model of GM1-gangliosidosis","volume":"27","author":"Przybilla","year":"2021","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/275754a0","article-title":"Enzyme replacement using liposome carriers in feline GM1 gangliosidosis fibroblasts","volume":"275","author":"Reynolds","year":"1978","journal-title":"Nature"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2147\/TACG.S206076","article-title":"Gm1 gangliosidosis: mechanisms and management","volume":"14","author":"Rha","year":"2021","journal-title":"Appl. Clin. Genet."},{"key":"ref50","doi-asserted-by":"publisher","first-page":"S265","DOI":"10.1016\/j.ymthe.2004.06.650","article-title":"Gene therapy of murine GM1 Gangliosidosis by genetically modified bone marrow hematopoietic progenitor cells","volume":"9","author":"Sano","year":"2004","journal-title":"Mol. Ther."},{"key":"ref51","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1182\/blood-2005-03-1189","article-title":"Chemokine-induced recruitment of genetically modified bone marrow cells into the CNS of GM1-gangliosidosis mice corrects neuronal pathology","volume":"106","author":"Sano","year":"2005","journal-title":"Blood"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.braindev.2008.11.004","article-title":"Intracerebral cell transplantation therapy for murine GM1 gangliosidosis","volume":"31","author":"Sawada","year":"2009","journal-title":"Brain and Development"},{"key":"ref53","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-66816-1_1752-1","article-title":"GM1 Gangliosidosis","volume-title":"Genetic Syndromes","author":"Senarathne","year":"2023"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s10545-005-0089-7","article-title":"Bone marrow transplantation correcting \u03b2-galactosidase activity does not influence neurological outcome in juvenile GM1-gangliosidosis","volume":"28","author":"Shield","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.addr.2017.05.004","article-title":"Lysosomal enzyme replacement therapies: historical development, clinical outcomes, and future perspectives","volume":"118","author":"Solomon","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"PMC.S2332","DOI":"10.4137\/PMC.S2332","article-title":"Chaperone therapy for Neuronopathic lysosomal diseases: Competitive inhibitors as chemical chaperones for enhancement of mutant enzyme activities","volume":"3","author":"Suzuki","year":"2009","journal-title":"Perspect. Medicin. Chem."},{"key":"ref57","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.3390\/cells11162579","article-title":"Preclinical enzyme replacement therapy with a recombinant \u03b2-galactosidase-lectin fusion for CNS delivery and treatment of GM1-Gangliosidosis","volume":"11","author":"Weesner","year":"2022","journal-title":"Cells"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1093\/hmg\/ddv168","article-title":"Systemic AAV9 gene transfer in adult GM1 gangliosidosis mice reduces lysosomal storage in CNS and extends lifespan","volume":"24","author":"Weismann","year":"2015","journal-title":"Hum. Mol. Genet."}],"container-title":["Frontiers in Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2024.1392683\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T04:34:30Z","timestamp":1714106070000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2024.1392683\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,26]]},"references-count":58,"alternative-id":["10.3389\/fnins.2024.1392683"],"URL":"https:\/\/doi.org\/10.3389\/fnins.2024.1392683","relation":{},"ISSN":["1662-453X"],"issn-type":[{"value":"1662-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,26]]},"article-number":"1392683"}}